Eaststone Limited have informed MHRA that the formula they have used to manufacture all batches of quetiapine oral suspension products is incorrect. The active content is twice the amount that it should be which could lead to overdosing. 

Eaststone Limited have clarified that a total of 166 units/bottles were manufactured between 26 October 2025 and 26 January 2026 and distributed to healthcare customers. The remainder of bottles have been quarantined and will not be supplied. This notification includes batches that have expired. Eaststone Limited have confirmed that they can trace supply to all healthcare customers who have been supplied with the impacted products.

Any patients who have taken batches, including both expired and non-expired should be reviewed. 

Patients should be advised not to stop any treatments without consulting their relevant healthcare professional and a treatment review should be initiated as soon as possible.

This National Patient Safety Alert provides further background, clinical information and actions for providers.